OPHI CollPlant Biotechnologies Ltd. - Ordinary Shares
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. The company offers regenerative dermal and soft tissue fillers; 3D-bioprinted regenerative breast implants; Collage, a combinant human Collagen type I solution; VergenixSTR, a soft tissue matrix for the treatment of tendinopathy; and VergenixFG, a wound care product for the treatment of deep surgical incisions and deep wounds. It also provides rhcollagen-based commercial bioink for regenerative medicine applications, such as Collink.3D 50L, a bioink in powder form; Collink.3D 90, an rhCollagen-based bioink solution for use in various 3D bioprinting applications; and Collink.3D 50, an rhCollagen-based bioink product. The company has collaboration agreements with AbbVie; STEMCELL; the Advanced Regenerative Manufacturing Institute; Stratasys; and RegenMed Development Organization. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.…
Key Statistics
About CollPlant Biotechnologies Ltd. - Ordinary Shares (NASDAQ: OPHI)
›
CollPlant Biotechnologies Ltd. - Ordinary Shares (NASDAQ: OPHI) is listed on Nasdaq, where its shares trade in USD. It reports about 39 employees.
The shares were at 3.650 USD on 13 November 2026. Its 52-week range is 3.600 USD to 4.250 USD: the price is 14.1% below the high and 1.4% above the low.
CollPlant Biotechnologies Ltd. - Ordinary Shares reports return on equity of -162.0% and revenue down 39.7% year over year.
Its debt exceeds its cash by 101.00K USD.